EQT Life Sciences (formerly known as LSP) is one of the largest European investment firms providing financing for life sciences and health care companies. EQT LS management has raised over €3 billion and supported the growth of 300 companies since it started to invest in 1988, including signature deals such as Qiagen, Argenx, Crucell, Okairos and Neuravi. With offices in Amsterdam, Munich and Boston, EQT LS currently has the possibility to invest through five strategies, each having a distinctive investment scope and a dedicated team: LSP 7 invests in private early- to late-stage drug development and medical technology companies; HEF 2 focuses on private late-stage medical technology companies; the LSP Dementia Fund invests in companies targeting neurodegenerative diseases; LSP Public targets public healthcare companies; and EBAC is the first healthcare SPAC to exclusively focus on European biotech. EQT LS is an active contributor to the global life sciences industry and the European life science eco-system by assuming for-profit and not-for-profit roles as initiators, founders and board members in various private and public bodies and organizations. We are part of the EQT group, a global leader in Private Equity and Healthcare Investing (www.eqtgroup.com).
Xilis, DNA Script, Artios Pharma, Cardior, eTheRNA, Orphazyme, Pharvaris, Immunic, Innovative Molecules, T Knife and many more
U3 - 2008 / Jerini - 2008 / Flow Cardia - 2010 / Okairos - 2013 / Sapiens - 2014 /
Prosensa - 2015 / Neuravi – 2017 / Arvelle Therapeutics - 2021/ Simplify Medical - 2021
Qiagen - 1996 / Rhein-Biotech - 1999 / Crucell - 2000 / deVGen - 2005 / Movetis -
2010/ Argenx - 2014/ Kiadis - 2015/ Orphazyme – 2017/ Sequana Medical - 2019/ Nkarta - 2020